Pfizer Corporation

Arbor Pharmaceuticals, LLC

Xenoport, Inc.

Asher Biotherapeutics, Inc.

Apple Inc.

Wei Chen

John Z Zhong

Christoph Horst Krah

Sami Karaborni

Suresh Kumar Manthati

Yik Andy Yeung

Arvind Rajpal

Pavel Strop

Thomas John Van Blarcom

Tracy Chia-Chien Kuo

Weihsien Ho

Edward Derrick Pascua

Amy Shaw-Ru Chen

Mark Edward Ruppen

Annaliesa Sybil Anderson

Shih-Chang Chang

Javier Fernando Chaparro Riggers

Leila Marie Boustany

Justin Keith Moran

Jianxin Gu

Avvari Krishna Prasad

Jin-Hwan Kim

Robert G K Donald

Jason Arnold Lotvin

Srinivas Kodali

Nishith Merchant

Ling Chu

Suddham Singh

Laurent Oliver Chorro

Rosalind Pan

Scott Ellis Lomberk

Karen Kiyoko Takane

Ivana Djuretic

Henry C Nguyen

Paul Bessette

Sherman Michael Chin

Kelly Dare Moynihan

Irene Ni

Danielle C Pappas

Terrence Park

Steven S Poon

Z Zhong John

Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.

Pharmaceutical compositions of dimethyl fumarate

In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived fromlipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for differentserotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

compositions and methods thereof

Provided herein are anti-CD8 antigen binding molecules and fusion polypeptides comprising the CD8 antigen binding molecules for selectively modulating the function of CD8+ T cells over other immune cells. In addition, the present disclosure also provides polynucleotides encoding the disclosed antigen binding molecules and fusion polypeptides, and vectors and host cells comprising such polynucleotides. The present disclosure further provides methods for producing the antigen binding molecules and fusion polypeptides, pharmaceutical compositions comprising the same, and uses thereof.

Fusions with CD8 antigen binding molecules for modulating immune cell function

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

Therapeutic antibodies and their uses

The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.

Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.

Pharmaceutical compositions of fumaric acid esters

Growing community of inventors

Cupertino, CA, United States of America

Wei Chen